DK2866797T3 - Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf - Google Patents

Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK2866797T3
DK2866797T3 DK12756353.4T DK12756353T DK2866797T3 DK 2866797 T3 DK2866797 T3 DK 2866797T3 DK 12756353 T DK12756353 T DK 12756353T DK 2866797 T3 DK2866797 T3 DK 2866797T3
Authority
DK
Denmark
Prior art keywords
injective
neurokinin
stable
preparation
pharmaceutical composition
Prior art date
Application number
DK12756353.4T
Other languages
English (en)
Inventor
Efthimos Koutris
Sotiria Chatidou
Amalia Diakidou
Panagiotis Barmpalexis
Louiza Konstanti
Katerina Minioti
Dimitrios Bikiaris
Evangelos Karavas
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Application granted granted Critical
Publication of DK2866797T3 publication Critical patent/DK2866797T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fencing (AREA)
DK12756353.4T 2012-07-06 2012-07-06 Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf DK2866797T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/002854 WO2014005606A1 (en) 2012-07-06 2012-07-06 Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof

Publications (1)

Publication Number Publication Date
DK2866797T3 true DK2866797T3 (da) 2020-08-03

Family

ID=46826407

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12756353.4T DK2866797T3 (da) 2012-07-06 2012-07-06 Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf

Country Status (14)

Country Link
US (2) US20150165045A1 (da)
EP (1) EP2866797B1 (da)
CY (1) CY1123370T1 (da)
DK (1) DK2866797T3 (da)
ES (1) ES2798103T3 (da)
HR (1) HRP20201138T1 (da)
HU (1) HUE051147T2 (da)
LT (1) LT2866797T (da)
PL (1) PL2866797T3 (da)
PT (1) PT2866797T (da)
RS (1) RS60599B1 (da)
SI (1) SI2866797T1 (da)
SM (1) SMT202000385T1 (da)
WO (1) WO2014005606A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054429A1 (en) 2013-10-08 2015-04-16 Innopharma, Inc Aprepitant oral liquid formulations
WO2015101596A2 (en) * 2013-12-30 2015-07-09 Oncoprevent Gmbh Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
EP3171894B1 (en) * 2014-07-24 2021-03-24 Plus Vitech, S.L. Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
WO2017021880A1 (en) * 2015-08-03 2017-02-09 Leiutis Pharmaceuticals Pvt Ltd Liquid formulations of fosaprepitant
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
KR20180118136A (ko) * 2016-02-01 2018-10-30 헤론 테라퓨틱스 인코포레이티드 Nk-1 수용체 길항제를 포함하는 에멀젼
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
PT3435980T (pt) * 2016-06-06 2020-02-21 Helsinn Healthcare Sa Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
US20190175702A1 (en) * 2016-08-03 2019-06-13 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
JP2021512091A (ja) * 2018-01-30 2021-05-13 ヘロン セラピューティクス, インコーポレイテッドHeron Therapeutics, Inc. Nk−1受容体アンタゴニストのエマルジョン製剤の投与方法
US11654154B2 (en) 2019-01-29 2023-05-23 Navinta Iii Inc Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability
CN112168788B (zh) * 2019-07-01 2022-07-19 中国医学科学院药物研究所 静脉注射用阿瑞匹坦胶束无菌冻干制剂及其制备方法
CN110559255B (zh) * 2019-09-06 2022-08-19 南京医科大学 Zl006温敏凝胶及其制备方法
WO2023197637A1 (en) * 2022-04-14 2023-10-19 Wisdom Pharmaceutical Co., Ltd. Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection
CN115944745B (zh) * 2022-12-01 2024-03-22 石河子大学 一种具有聚集诱导发光性质的活性氧响应型药物控释体系及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082959A1 (en) 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
JP2008517927A (ja) * 2004-10-21 2008-05-29 ユニバーシティー オブ アイオワ リサーチ ファンデーション insitu制御放出薬剤送達システム
US9227958B2 (en) * 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
WO2007128056A1 (en) * 2006-05-03 2007-11-15 Cnsbio Pty Ltd Methods and composition for treatment of inflammatory pain
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
ES2620672T3 (es) * 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
EP2310019A4 (en) * 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
WO2011006012A1 (en) * 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation

Also Published As

Publication number Publication date
HRP20201138T1 (hr) 2020-10-30
WO2014005606A1 (en) 2014-01-09
EP2866797B1 (en) 2020-04-29
CY1123370T1 (el) 2021-12-31
RS60599B1 (sr) 2020-08-31
PT2866797T (pt) 2020-07-22
SI2866797T1 (sl) 2020-08-31
US20150165045A1 (en) 2015-06-18
PL2866797T3 (pl) 2020-11-02
LT2866797T (lt) 2020-06-25
HUE051147T2 (hu) 2021-03-01
ES2798103T3 (es) 2020-12-09
US20200237920A1 (en) 2020-07-30
SMT202000385T1 (it) 2020-11-10
EP2866797A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
DK2866797T3 (da) Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf
IL274798A (en) Ph20 polypeptide variants, formulations and uses thereof
HUE051400T2 (hu) Lipofil gyógyászati szerek javított parenterális kiszerelései és eljárások azok elõállítására és alkalmazására
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
DK2877599T3 (da) Fremgangsmåder og sammensætninger til bestemmelse af resistens overfor androgenreceptorterapi
HUE053360T2 (hu) Kompozíciók és eljárások mutációk pontos azonosítására
PL2922526T3 (pl) Wytwarzanie półplastycznych farmaceutycznych jednostek dawkowania
ME03465B (me) Farmaceutska kompozicija s-ketamin hidrohlorida
LT3222272T (lt) Farmacinė karbetocino kompozicija
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
HUE037664T2 (hu) Állati takarmány és eljárás annak elõállítására
DK2917358T3 (da) Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater
IL229963A0 (en) Substituted quinolines and their use as medicaments
HRP20180915T1 (hr) Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
HUE056943T2 (hu) CCR3 antagonistákat tartalmazó gyógyászati készítmények
DK2815752T3 (da) Oral farmaceutisk sammensætning
EP2925340A4 (en) Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor
BR112013033472A2 (pt) derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação
FI20125888A7 (fi) Anisomelihapon farmaseuttiset koostumukset ja niiden käyttö
SMT201500005B (it) Composizione framaceutica inalabile
DK2525827T3 (da) Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf
PL2956011T3 (pl) Kompozycja do żucia do podawania doustnego i sposób jej wytwarzania
DK3517532T3 (da) Fremgangsmåde til fremstilling af anamorelinhydrochlorid med reguleret chloridindhold